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INTRODUCTION 
Introduction to drug delivery system 
Historically, the oral route of administration has been used the most for both 
conventional and novel drug delivery system. These systems have the obvious 
advantages of ease of administration and patient acceptance, least sterility constraints 
and flexibility in the design of dosage form. One would always like to have an ideal drug 
delivery system  that  will  possess two main properties: 
• It will be a single dose for the whole duration of treatment. 
• It will deliver the active drug directly at the site of action. 
Unfortunately, such ideal systems are not available.  Thus scientists try to 
develop systems that can be  as close to an ideal system as possible. More than 50% of 
drugs, available in the market are meant for oral administration. The conventional  drug  
therapy  results in fluctuation of drug concentration in systemic circulation, causing 
either toxic effect or no therapeutic effect. 
Now recent scientific and technological advancement have been made in the 
research and develop of rate controlled oral drug delivery systems by overcoming 
physiological adversities and short gastric residence  time. Invariably, conventional drug 
dosage forms do not maintain the drug blood levels within  the  therapeutic range for an 
extended period of time. To achieve the same, a drug may be administered repetitively 
using a fixed dosing interval. This causes several potential problems like saw tooth 
kinetics characterized by large peaks and troughs in the drug concentration-time curve 
frequent dosing  for  drugs  with short biologic half-life, and above all the patient non 
compliance. Now recent scientific and  technological advancement have been made in 
the research and develop of rate controlled oral drug  delivery systems by overcoming 
physiological adversities and short gastric residence time [1].Invariably, conventional 
drug dosage forms do not maintain the drug blood levels within the therapeutic range for 
an extended period of  time. 
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Anatomy of the stomach 
The gastro intestinal tract can be divided into three main regions 
 Stomach 
 Small intestine- duodenum, jejunum, and ileum 
 Large intestine. 
 
                                 Figure 1: Shows parts of Stomach 
The git is a muscular tube of about 9m which extends from mouth to anus. Its 
function is to take nutrients and eliminate out waste product by physiological processes 
such as digestion, absorption, secretion, motility and excretion. The stomach has three 
muscle layer called oblique muscle and it is situated in the proximal part of the stomach, 
branching over the fundus and higher regions  of  the  gastric  body.  The  stomach  is 
divided into fundus, body and pylorus[2]. The stomach is a J shaped organ located in 
the upper left hand portion of the abdomen. The main function of the stomach is to store 
the food temporarily , grind it and releases slowly in to the duodenum. 
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Physiology of the stomach 
The stomach is an expanded section of the digestive tube between the 
esophagus and small intestine.  In the empty state the stomach is contracted and its 
mucosa and sub mucosa are thrown up into folds called rugae. There are 4 major types 
of secretary epithelial cells that covers the stomach and extends into gastric pits and 
glands. 
1. mucous cells- secrete alkaline mucus 
2. parietal cells – secrete HCL 
3. chief cells- secrete pepsin 
4. G cells- secrete hormone gastrin[3]. 
Physiology of gastrointestinal tract 
Anatomically the stomach  is  divided  into  three regions: fundus, body, and 
antrum (pylorus). The proximal part made up of fundus and body acts as a reservoir for 
undigested material, whereas the antrum is the main site for mixing motions and act as 
a pump for gastric emptying by propelling  actions.  Gastric emptying occurs during 
fasting as well as fed  states. The pattern of motility is however distinct in the two states. 
During the fasting state an inter digestive series of electrical  events  take  place,  which  
cycle  both  through  stomach  and intestine every 2 to 3 hours. 
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Fig2: Physiology of Gastrointestinal Tract 
This is called the inter digestive myloelectric cycle or migrating myloelectric 
cycle (MMC), which is further divided into following 4 phases as described by 
Wilson and Washington. 
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions. 
2. Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent 
action potential and  contractions. As the phase progresses the intensity and 
frequency also increases gradually. 
3. Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and 
regular contractions for  short period. It is due to this wave that all the undigested 
material is swept out of the  stomach  down  to  the  small intestine. It is also 
known as  the  housekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes  and  occurs  between phases  III and  I 
of 2 consecutive cycles [16]. 
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Gastric emptying and problems 
The process of the gastric emptying occurs both during fasting and fed stages. 
Scintinography  study  involving  measurement  of gastric  emptying  rates  in  
healthy   human   subject have  revealed  that  an  orally  administered  Controlled 
release dosage form is mainly subjected to two physiological adversities, 
The short GRT (Gastric Residence Time) 
Variable (unpredictable) GET (Gastric Emptying Time) 
 
                        Fig 3: Motility patterns of the GIT in fasted state 
 
Table 1.1: salient features of upper gastrointestinal tract 
Section 
Length 
(m) 
Transit 
(h) 
time pH 
Microbial 
count 
Absorbing 
surface 
are
a 
Absorption 
pathway 
      (m2)   
Stomach 0.2 Variable  1-4 <103 0.1  P, C, A 
Small 
Intestine 
6-10 3 ± 1  5-7.5 103 – 1010 120-200  P, C, A, F, I, E, 
CM 
 
P – Passive diffusion ,C – Aqueous channel transport ,A – Active transport, F-  Facilitated transport,  
I –  Ion-pair   transport ,E – Entero-or pinocytosis ,CM –  Carrier mediated transport 
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The basic rationale of the controlled drug delivery system (CDDS) is to optimize 
the  biopharmaceutic, pharmacokinetic  and pharmacodynamic properties of a drug in 
such a way that its utility is maximized through reduction in side effects and cure or 
control of condition in the shortest possible time by using smallest quantity of drug 
administered by the most suitable route [4]. Controlled release drug administration 
means not only the prolongation of the duration of drug delivery, similar to the objective 
in sustained release and prolonged release, but the term also implies the predictability 
and reproducibility of drug release kinetics. Oral controlled release drug delivery 
system that provides the continuous oral delivery of drugs at predictable and 
reproducible kinetics for a pre-determined period throughout the course of GI transit. 
Controlled release denotes the system in which release rate of the drug from the 
system is temporal (related to time ) or spatial ( related to site) nature or both. In other 
words system attempts to control the drug concentration in the target tissue or cells. 
 
Fig 4:Plasma level  profiles  following conventional and controlled release dosing. 
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The broad objectives of controlled release drug delivery system are as follows 
 Prolongs the duration of action of the  drug at a predetermined rate by 
maintaining a relatively  constant, effective drug level in the body with the 
minimization of the adverse effect associated with a peak valley kinetic 
pattern. 
 Localization of drug action by spatial placement of controlled releas 
 system near to or in the diseased tissue or organ , site or even receptor. 
Target drug action by using carrier or chemical derivatization to deliver drug to a 
particular target , cell type. Ideally it is desirable to release the drug at the target sites 
whether it is a tissue , population of cells or receptors , leaving rest of the  body drug 
free [3]. 
 
Merits of Controlled Drug Delivery 
• Reduction in fluctuation in steady state levels and therefore better 
control of disease and Reduce intensity of local or systemic side 
effect. 
• Improved patient compliance. 
• Reduced dosing frequency. 
• More consistent and  prolonged therapeutic effect. 
• Decreased incidence and/or intensity of adverse effects and toxicity. 
• Better drug utilization. 
• Controlled rate and site of release. 
• Reduce wastage of the drugs. 
• More uniform blood concentrations. 
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• Less therapeutic index. 
• A greater selectivity of pharmacological activity.[4] 
Demerits of Controlled Drug Delivery 
• Toxicity due to dose dumping. 
• Increased cost. 
• Increased variability among dosage units. 
• Stability problems. 
• Retrieval of drugs in difficult in case of toxicity, poisoning or 
hypersensitivity reactions [5]. 
Classification of oral controlled drug delivery system 
Oral controlled drug delivery systems can be broadly classified on the basis of  
their  mechanism  of  drug  release.  Primarily, controlled release is achieved by 
diffusion, degradation and swelling followed by diffusion. Any or all of these 
mechanisms may occur in a given release systems. Diffusion occurs when bioactive 
agent passes through the polymer, which forms the building block of controlled 
release system. 
1. Dissolution-controlled release 
a) Encapsulation Encapsulation dissolution control 
b) Matrix dissolution control 
2. Diffusion-controlled release 
a) Reservoir devices 
b) Matrix devices 
3. Osmotic controlled release 
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4. Ion exchange resins 
5. Gastroretentive systems 
Gastro retentive Systems 
Variability in GI transit time  is  a  concern  for  oral controlled drug delivery 
systems. A major constraint in oral controlled release drug delivery  is that not all the 
drug candidates are absorbed uniformly throughout the GIT (gastrointestinal tract). 
Some drugs are absorbed in a particular portion of GI tract only or absorbed to a 
different extent in various segments of GI tract. Such drugs are said to have an  
absorption  window.  Thus  only the drugs which are  released  in  the preceding region 
and in close vicinity to the absorption window are available for absorption. After crossing 
the absorption window, the release drug goes to waste with negligible or no absorption. 
Thus the time available for drug absorption drastically decreases. 
Gastro retentive dosage form 
Gastro retentive dosage forms are the systems that can stay in the gastric 
region for several hours and thus, prolong the gastric residence time of the drugs. 
After oral administration, such a dosage form is retained in the stomach and releases 
the drug in a controlled and sustained manner so that the drug can be supplied 
continuously in the upper GIT. This prolonged gastric retention improves 
bioavailability, decreases drug wastage, and improves solubility of drugs that are less 
soluble in a high pH environment [6].Gastro retentive  systems can remain in the 
gastric  region  for several hours and hence significantly prolong the gastric residence 
time of drugs. Prolonged gastric retention improves bioavailability, reduces drug 
waste, and improves solubility for drugs  that    are less soluble in a high pH 
environment. It has applications also for local drug delivery to the stomach and 
proximal small intestines. Gastro retention helps to provide better availability  of new 
products with new therapeutic possibilities and substantial benefits for patients (7).                                 
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Fig 5: Gastro retentive approaches Fig 6: Gastrointestinal Tract-General 
 
Gastric emptying of dosage forms is an extremely variable process and ability 
to prolong and control the emptying time is a valuable asset  for  dosage forms, which 
reside in the stomach for a longer period of time than conventional dosage forms. 
Several difficulties are faced in designing controlled release systems for better 
absorption  and enhanced bioavailability. One of such difficulties is the inability to 
confine the dosage form in the desired area of the gastrointestinal  tract. One of the 
most feasible approaches for achieving and predictable drug delivery profile in GIT is 
to control the GRT so  that  gastric  emptying process can be extended from few 
minutes to 12 hr using GRDF’s that offers new  and  better  option  for  drug  
therapy(8-11). 
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Gastric retention can be achieved by mechanism of mucoadhesion or bio 
adhesion, expansion system, super porous hydro gels, raft forming system, low density 
system, floatation and simultaneous administration of pharmacological agents that 
delay the gastric emptying [12]. 
Potential candidates for gastro retentive drug delivery system 
 Drugs that are primarily absorbed in the stomach eg Amoxicillin. 
 Drugs that are poorly soluble in alkaline pH eg Furosemide , Diazepam. 
 Drugs that have narrow absorption window eg Levodopa, Methotrexate. 
 Drugs that degrade in the colon eg Ranitidine , Metformin HCL 
 Drugs that disturb normal colonic microbes eg Antibiotics against 
Helicobacter pylori. 
 Drugs rapidly absorbed from the gi tract eg Tetracycline. 
 Drugs acting locally in the stomach eg Misoprostol [13]. 
Gastroretentive technologies 
A number of systems have been pursued to  increase the GRT  of  dosage forms 
by employing  a variety of concepts. These systems have been classified according to 
the basic principles of gastric retention.(14) 
Expandable systems 
These GRDFs are easily swallowed and reach a significantly larger size in the 
stomach due to swelling or  unfolding  processes  that  prolong their GRT. After drug 
release,  their  dimensions are minimized with subsequent evacuation  from the 
stomach.(15) 
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Bio/Muco-adhesive systems 
This approach involves the use of bioadhesive polymers, which can adhere to 
the epithelial surface in the stomach. The proposed mechanism  of bioadhesive is the 
formation of hydrogen and electrostatic bonding at the mucus polymer boundary[18]. 
High-density systems 
Sedimentation has been employed as a retention mechanism for pellets that are 
small enough to be retained in the rugae or folds  of  the  stomach  body near the 
pyloric region. Commonly used excipients are Barium sulphate, Zinc oxide, Titanium 
dioxide and Iron powder, These  materials  increase  density  by  up  to1.5– 
2.4g/cm3(19). 
Limitations of gastroretentive drug delivery  system 
1. Aspirin and NSAID’S can cause gastric lesions and slow release of such 
drug in the stomach is unwanted. 
2. Drugs such as isosorbide dinitrate which are equally absorbed throughout 
the GIT will not be benefit from incorporation into a gastric retention system. 
3. Bioadhesion in the acidic environment and high turnover of mucus may 
raise questions about the effectiveness of the technique 
4. Physical integrity of the system is very important and primary requirement 
for the success of the system. 
5. High variability in gastric emptying time due to variations in emptying 
process , unpredictable bioavailbility. 
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Advantages of gastro retentive drug delivery system 
1. It increases patient compliance by reducing dosing frequency 
2. Buoyancy increases gastric  residence time 
3. Better therapeutic effect of short half life drugs 
4. Site specific drug delivery to stomach can be achieved 
5. In this drug is released in a controlled manner 
6. Gastric irritation can be avoided by designing sustained release 
7. No risk of dose dumping by making single unit floating unit such as 
microspheres releases drug uniformly. (1,17) 
Factors affecting gastric retention  
Density of dosage form 
The density of a dosage form also affects the gastric emptying rate. A buoyant 
dosage form having a density  of  less  than  that  of  the  gastric  fluids (≅1.004 gm/ml) 
floats. Since it is away from the pyloric sphincter, the dosage unit is retained in the 
stomach for a prolonged period. 
Size and shape of dosage form 
To pass through the pyloric valve into the small intestine the particle size should be 
in the range of 1 to 2 mm. Dosage form unit with a diameter of more than 7.5 mm are 
reported to have an increased GRT compared to those with a diameter of 9.9 mm. The 
dosage form with a shape tetrahedron and ring shape devices with a flexural modulus of 
48 and 22.5 kilopond per square inch (KSI) are reported to have better GIT (≅ 90 to 100 
%) retention at 24 hours compared with other shapes [18]. 
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Fasting or fed state 
Under fasting conditions, the GI motility is characterized by periods of strong motor 
activity or the migrating myoelectric complexes (MMC) that occurs every 1.5 to 2 hours. 
The MMC sweeps undigested material from the stomach and if the timing of 
administration of the  formulation coincides with that of the MMC, the GRT of the unit can 
be expected to be very short. However, in the fed state, MMC is delayed and GRT is 
considerably longer. The pH of the stomach in fasting state is ~1.5 to 2.0 and in fed state 
is 2.0    to 6.0. A large volume  of  water  administered   with an oral dosage form raises 
the pH of stomach contents to 6.0 to 9.0. Stomach doesn’t get time to produce sufficient 
acid when the liquid empties the stomach; hence generally basic drugs have a better 
chance of dissolving in fed state than in a fasting state [19]. 
Nature of the meal (food) 
 The rate of gastric emptying depends mainly on viscosity, volume, and caloric 
content of meals. Nutritive density of meals helps determine gastric emptying time. It 
does not make any difference whether the meal has high protein, fat, or carbohydrate 
content  as  long  as  the  caloric content  is  the same. 
Effect of liquid, digestible solid and indigestible solid type food 
It has been demonstrated using radio labeled technique that there is a difference 
between gastric emptying  times  of  a  liquid,  digestible  solid,  and indigestible solid. It 
was suggested that the  emptying of large (>1 mm) indigestible objects from stomach 
was dependent upon inter digestive migrating myoelectric complex. 
Biological factors 
Biological factors such as age, body mass index (BMI), gender, posture, and 
diseased states (diabetes, Chron’s disease) influence gastric emptying. In the case of 
elderly persons, gastric emptying is slowed down. Generally females have slower gastric 
emptying rates than males. GRT can vary between supine and upright ambulatory states 
of the patients. Stress increases gastric emptying rates while depression slows it down 
[20]. 
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Frequency of feed 
The gastro retentive time can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC. 
Gender 
Mean ambulatory GRT in meals (3.4 ± 0.4 hours) is less compared with their age 
and race-matched female counterparts (4.6± 1.2 hours), regardless of the weight, height 
and body surface [21]. 
Posture 
Gastro retentive time can vary between supine and upright ambulatory states of 
the patients. [22]. 
FLOATING DRUG DELIVERY SYSTEM 
The floating sustained release dosage forms present most of the characteristics 
of hydrophilic  matrices and are known as ‘hydro dynamically balanced systems’ (‘HBS’) 
since they are able to maintain their low apparent density, while the polymer hydrates 
and builds a gelled barrier at the outer surface. The drug  is released progressively from 
the swollen matrix, as in the case of conventional hydrophilic matrices. These forms are 
expected to remain buoyant (3- 4 hours) on the gastric contents without affecting the 
intrinsic rate of emptying because their bulk density  is lower than that of the gastric 
contents. Many results have demonstrated the validity of the concept of buoyancy in 
terms of prolonged GRT of the floating forms, improved bioavailability of drugs  and 
improved clinical situations. These results also demonstrate that the presence of gastric 
content is needed to allow the proper achievement of the buoyancy retention principle.  
Among the different hydrocolloids recommended for floating form formulations, 
cellulose ether polymers are most popular, especially hydroxyl propyl methyl celluloses. 
Fatty material with a bulk density lower than one may be added to the formulation to 
decrease the water intake  rate and increase buoyancy [23]. 
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Parallel to formulation studies, investigations have been undertaken in animals 
and humans to evaluate the intra gastric retention performances of floating forms. 
These assessments were realized either indirectly through  pharmacokinetic studies 
with a drug tracer, or directly by means of X-ray and gamma scintigraphic monitoring of 
the form transit in the GI tract. When a floating capsule is administered to the subjects 
with a fat and protein meal, it can be observed  that  it  remains buoyant  at  the surface 
of  the gastric content in the upper part of the stomach and moves down progressively 
while the meal empties. The reported gastric retention times range from 4 to 10  hours. 
Pharmacokinetic and bioavailability evaluation studies confirm the favorable incidence 
of this prolonged gastric residence time [24]. 
 
Fig 7: Various forms of gastro retentive systems; (a) Floating gastro retentive 
drug delivery systems; (b) Swelling gastro-retentive drug delivery systems; (c)  
Bio  adhesive  gastro-retentive  drug  delivery  systems;  (d)  High- density 
gastroretentive drug delivery systems. 
Floating drug delivery systems (FDDS) have a  bulk density less than  gastric  
fluids  and  so remain buoyant in the stomach without affecting gastric emptying rate for 
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a prolonged period of time. While the system is floating on the gastric contents, the drug 
is released  slowly  at  the desired rate from the system.  After  release  of drug, the 
residual system is emptied from the stomach. This results in an increased GRT and a 
better control of the fluctuations in plasma drug concentration.[25] 
Classification of floating drug delivery system (FDDS)  
Based  on  the  mechanism  of   buoyancy,   two  distinctly different technologies have 
been utilized in development of FDDS, which are 
 A. Effervescent System, and 
 B. Non- Effervescent System. 
 
Effervescent System 
These are the matrix types of with   the   help   of   swellable systems prepared 
polymers  such  as methylcellulose and chitosan and various effervescent  
compounds, eg, sodium bicarbonate tartaric acid, and citric acid. They are 
formulated in  a such  a way that  when in   contact with   the   acidic   gastric  contents,  
CO2 is liberated  and  entrapped  in  swollen  hydrocolloids, which provides buoyancy to 
the dosage forms [26] 
I. Gas Generating systems 
II. Volatile Liquid/Vacuum Containing Systems 
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Figure 8: Shows working of effervescent FDDS 
Gas – Generating Systems 
Intra Gastric Single Layer Floating Tablets    or Hydro dynamically 
Balanced System 
These  are  formulated  by  intimately  mixing   the CO2  generating agents and  
the  drug  within  the matrix  tablet.  These  have  a  bulk  density   lower than gastric 
fluids and therefore remain floating in the stomach for a prolonged period. 
Intra Gastric Bi-layer Floating Tablet 
These are also compressed tablet containing two layers i.e., Immediate release 
layer,  Sustained release layer. These are as formulated by intimately mixing the CO2 
generating agents and the drug within the matrix tablet. 
Multiple Unit type floating pills 
The system consists of sustained release pills    as ‘seeds’ surrounded by 
double layers. The inner layer consists of effervescent agents while the outer layer is 
of swellable membrane layer. When the system is immersed in dissolution medium at 
body temp, it sinks at once and then forms  swollen pills like balloons, which float as 
they have lower density. This lower density is due to generation and entrapment of 
CO2 within the system. 
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Inflatable Gastrointestinal Delivery Systems 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause  the chamber to inflate in the stomach.  
These  systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug impregnated polymeric matrix, encapsulated in a gelatin capsule.  
After oral administration,  the capsule dissolves to release the drug reservoir together 
with the inflatable chamber. The inflatable chamber automatically inflates and retains 
the drug reservoir compartment in the stomach. The drug continuously released  from 
the    reservoir    into    the    gastric    fluid   [27]. 
 
 
 
 
 
                   Fig 9: Inflatable Gastrointestinal Delivery System 
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Intra-gastric Osmotically Controlled Drug Delivery System 
It is comprised of an osmotic pressure  controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intra- gastric osmotically controlled drug delivery device[23]. 
The inflatable support inside forms a deformable hollow polymeric bag that contains a 
liquid that gasifies at body temperature to inflate the bag. The osmotic pressure controlled 
drug delivery device consists of two components; drug reservoir compartment  and  an 
osmotically active compartment. The drug reservoir compartment is enclosed by a 
pressure responsive collapsible bag, which is impermeable to vapour and liquid and has a 
drug delivery orifice. The osmotically active compartment contains an osmotically active 
salt and is enclosed within a semi permeable housing. In the stomach, the water in the GI 
fluid is continuously absorbed through the semi permeable membrane into osmotically 
active compartment to dissolve the osmotically active salt[28].  
The osmotic pressure thus created acts on the collapsible bag and in turn forces 
the drug reservoir compartment to reduce its volume and activate drug release through 
the  delivery orifice. The floating support is also made to contain a bioerodible plug that 
erodes after predetermined time to deflate the support. The deflated drug delivery system 
is then emptied from the stomach [29]. 
 
Fig 10: Intragastric Osmotically Controlled Drug Delivery System 
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Non Effervescent System 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or bio 
adhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel  forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming material such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymer such as 
chitosan and carbopol [30]. 
Working principle of this type of FDDS 
Capsule/tablet contains a mixture of drug and hydrocolloids. Upon contact with 
gastric fluid, the mixture swells and forms a gelatinous  barrier thereby remaining 
buoyant in the gastric juice for an extended period of time[31]. 
Various types of non effervescent floating Single Layer Floating Tablets 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity[32]. 
Bi-layer Floating Tablets 
A bi-layer  tablet  contain  two layer  one immediate release layer which releases 
initial dose from the system while another sustained release layer absorbs gastric fluid, 
forming an impermeable colloidal gel barrier on its surface, and maintain a bulk density 
of less than unity and thereby it remains buoyant in the stomach[33]. 
Alginate Beads 
Multi unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping sodium alginate solution into aqueous solution of calcium chloride,  causing  
precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hours [34]. 
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Hollow Microspheres 
Hollow microspheres (microballoons), loaded with drug in their outer polymer 
shells are prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueous solution of PVA that is thermally  controlled at 400C. 
Formulation of floating dosage form 
Following    types    of    the    ingredients    can   be incorporated in to HBS 
dosage form in addition to drugs. 
 Hydrocolloids 
 Inert fatty materials 
 Release rate accelerants 
 Release rate retardant 
 Buoyancy increasing agents 
 Miscellaneous [35]. 
Advantages of floating dosage forms Enhanced bioavailability 
The bioavailability of Riboflavin CR-GRDF is significantly enhanced in 
comparison to the administration of non-GRDF CR polymeric formulations. There are 
several different processes, related to absorption and transit of the drug in the 
gastrointestinal tract, that act concomitantly to influence  the magnitude of drug 
absorption. 
Enhanced first-pass biotransformation 
In a similar fashion to the increased efficacy of active transporters exhibiting 
capacity limited activity, the pre-systemic metabolism of the tested compound may be 
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considerably increased when the drug is presented to the metabolic enzymes 
(cytochrome P450, in particular CYP3A4) in a sustained manner, rather than by a bolus 
input [37]. 
Sustained drug delivery/reduced frequency of dosing 
For drugs with relatively short biological half-life, sustained and slow input from 
CR-GRDF may  result in a flip-flop pharmacokinetics and enable reduced dosing 
frequency. This feature is associated with improved patient compliance, and thereby 
improves therapy. 
Reduced fluctuations of drug concentration  
Continuous input of the drug following CRGRDF administration produces blood 
drug concentrations within a narrower range compared to the immediate release 
dosage forms. Thus, fluctuations in drug effects are minimized and concentration 
dependent adverse effects that are associated with peak concentrations can be 
prevented. This feature is of special importance for drugs with a narrow therapeutic 
index [38].  
Improved selectivity in receptor activation 
Minimization of fluctuations in drug concentration also makes it possible to obtain 
certain selectivity in the elicited pharmacological effect of drugs that activate different 
types of receptors at different concentrations. 
Reduced counter-activity of the body 
In many cases, the pharmacological response which intervenes with the natural 
physiologic processes provokes a rebound activity of the body that minimizes drug 
activity. Slow input of the drug into the body was shown to minimize the counter activity 
leading to higher drug efficiency. 
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Extended time over critical (effective) concentration 
For certain drugs that have non-concentration dependent pharmacodynamics, 
such as beta lactam antibiotics, the clinical response is not associated with peak 
concentration, but rather with the duration of time over a critical therapeutic 
concentration. The sustained mode of administration enables extension of the time over 
a critical concentration and thus enhances the pharmacological effects and improves the 
clinical outcomes.[39] 
Site specific drug delivery 
A floating dosage form is a feasible approach especially for drugs which have 
limited absorption sites in upper small intestine. The controlled, slow delivery of drug to 
the stomach provides sufficient local therapeutic levels and limits the systemic 
exposure to the drug. This reduces side effects that are caused by the drug in the 
blood circulation. In addition, the prolonged gastric availability from a site directed 
delivery system may also reduce the dosing frequency [40]. 
Disadvantages of floating dosage forms 
 These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently-coat, water. 
 Not suitable for drugs that have solubility or stability problem in GIT. 
 Drugs such as Nifedipine which is well absorbed along the entire GIT and which 
undergoes first pass metabolism, may not be desirable. 
 Drugs which are irritant to Gastric mucosa is also not desirable or suitable. 
 The drug substances that are unstable  in the acidic environment of the 
stomach are not suitable candidates  to be incorporated in the systems. 
 The dosage form should be administered with a full glass of water (200-250 ml). 
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 These systems do not offer significant advantages over the conventional dosage 
forms for drugs, which are absorbed through out the gastrointestinal tract [41]. 
Evaluation of floating drug delivery system  
Various parameters that need to be evaluated in gastro-retentive  formulations  
include floating duration, dissolution profiles, specific gravity, content uniformity, 
hardness, and friability in case  of solid dosage forms. In the case of multiparticulate drug 
delivery systems, differential scanning calorimetry (DSC), particle size analysis, flow 
properties, surface morphology, and mechanical properties are also performed. 
Floating time 
The test for buoyancy is usually performed in simulated gastric and intestinal fluid 
maintained at 37ºC. The floating time is determined by using USP dissolution apparatus 
containing 900 ml of 0.1 N HCl as the testing medium maintained at 37ºC . The time for 
which the dosage form floats is termed as the floating or floatation time [42]. 
Swelling index 
The swelling index of tablets was determined in 0.1 N HCl (pH 1.2) at room 
temperature. The swollen weight of the tablets was determined at predefined time 
intervals. The swelling index was calculated by the following equation: 
Swelling Index=Wt-Wo…..eq (vi) 
Wt 
Where, W0 is the initial weight of tablet, and Wt is the  weight    of         the         
tablet  at time t. 
In-vitro release studies 
The release rate of floating drug delivery system was determined in dissolution 
apparatus. Different types of dissolution apparatus are used according to formulation. 
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The dissolution fluid was maintained at 37 ± 1°C at a rotation speed. Perfect sink 
conditions prevailed during the drug release study [43]. 
In-vivo study 
In vivo gastric residence time of a floating dosage form is determined by X-ray 
diffraction studies, gamma scintigraphy, or roentgenography. In X-ray method the 
formulation is modified to incorporate Barium Sulphate as X-ray opaque substance. The 
study is carried out by administering the gastro retentive tablets to human volunteer [44]. 
The tablet was administered in the fasting state. The X-Ray opaque formulation is 
administered along with 250 ml of water. The subjects are allowed to remain in sitting or 
upright position. A light meal is given to volunteer 2 hour after administration of the tablet 
to evaluate effect of food of gastro retentive property. The position of tablet is monitored 
by X-Ray screening technique X-Ray photographs taken at desired intervals to monitor 
tablet position in human gastrointestinal tract [45]. 
X-ray / gamma scintigraphy 
It helps to locate dosage form in the GIT by which one can predict and 
correlate the gastric emptying time and the passage of dosage form in the git. The 
inclusion of a radio opaque material into solid dosage form enables it to be visualized 
by the X-ray[45]. The inclusion of a gamma emitting radionuclide in the formulation 
allows indirect external observation using gamma camera, the gamma rays emitted 
by radionuclide is focused on the camera which helps to monitor the location of the 
dosage form[46]. 
Gastroscopy 
It comprises of peroral endoscopy used with a fibereoptic and video system. It 
is used to inspect visually the effect of prolonged stay in stomach milieu on the FDDS 
[45][47]. 
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Future potentials 
 The floating drug delivery concept can be used in development of anti reflux 
formulations 
 Buoyant delivery system is beneficial in the treatment of gastric and 
duodenal ulcers. 
 Developing a controlled release of drugs which is used to treat Parkinson 
disease. 
 To explore the eradication of helicobacter pylori by using narrow spectrum 
  antibiotic. 
Controlled release drug administration means not only the prolongation of the 
duration of drug  delivery,  similar to the objective in sustained release and prolonged 
release, but the term also implies the predictability and reproducibility of drug release  
kinetics. Oral controlled release drug delivery  system that provides the continuous 
oral delivery of drugs at predictable and reproducible kinetics for a pre- determined 
period throughout the course of GI transit. Gastro retentive dosage forms are the 
systems that can stay in the gastric region for several hours and thus, prolong the 
gastric residence time of the drugs. After  oral administration, such a dosage form is 
retained  in the stomach and releases the drug in a controlled and sustained manner 
so that the drug can be supplied continuously in the upper GIT. This prolonged 
gastric retention improves bioavailability, decreases drug wastage, and improves 
solubility of drugs that are less soluble in a high pH environment.  
Gastric emptying  of dosage forms is an extremely variable process and ability to 
prolong and control the emptying time is a valuable asset for dosage forms, which 
reside in the stomach  for  a  longer  period  of  time  than conventional dosage forms. 
Several  difficulties  are faced in designing  controlled  release  systems  for  better   
absorption   and   enhanced   bioavailability.    One of such difficulties is the inability to 
confine the dosage form in the desired area of the gastrointestinal tract. One of the most 
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feasible  approaches  for  achieving and predictable  drug  delivery  profile  in  GIT is to 
control the GRT so that gastric emptying process can be extended from few minutes to 
12  hr using GRDF’s that offers   new   and   better  option   for drug therapy. 
Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption 
from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II 
receptor antagonist. Angiotensin II is formed from angiotensin I in a reaction catalyzed  
by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal 
pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, 
stimulation of  synthesis  and  release of aldosterone, cardiac stimulation and  renal 
reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II 
by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular 
smooth muscle. Its action is, therefore, independent of the pathways for  angiotensin II 
synthesis. Olmesartan medoxomilis indicated for the treatment of mild to moderate 
essential hypertension.  
The absolute bioavailability of olmesartan is approximately 26%. After oral 
administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 
to 2 hours. Food does not affect the  bioavailability of olmesartan. Olmesartan 
medoxomil inhibits the pressor effect of an angiotensin II infusion   in a dose- dependent 
manner at doses of 2.5 to 40 mg. The inhibition was 90% at doses of olmesartan 
medoxomil >40 mg 24 hours post  dose. 
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AIM AND OBJECTIVE 
Aim of present research is development of formulation, optimization and 
evaluation of gastro retentive floating drug delivery system of olmesarten medxomil. 
The objective of the present study was to develop an optimized gastroretentive 
floating drug delivery  system of Olmesartan Medoxomil and investigate the effect of 
hydrophilic retardant on invitro release by using 32 full factorial design. 
Floating tablets of olmesartan medoxomil were  prepared  by direct  compression 
method using effervescent technique by employing two different grades of HPMC. 
(HPMC K4M  and  HPMC  K100M). Sodium bicarbonate was  incorporated as gas 
generating agent. 
The concentration of  HPMC K4M (X1)     and concentration of HPMC K100M 
(X2) were selected as independent variables. The floating lag time,  total  floating time 
and t ime taken  to  80 %  drug  release  were  selected  as  dependent  variables. 
Targets were defined for each  response so  as  to select the  optimam formula using 
numerical  optimization. 
All  the  floating  matrix tablets  formulations  were  subjected  to  pre-
compression  and  post-compression  parameter  evaluation.  
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LITERATURE REVIEW 
A.Hemdan et al., validated chromatographic method for determination of some 
anti-hypertensive drugs. Accurate, precise and reproducible isocratic RP-HPLC method 
was developed and subsequent validated for the analysis of Torasemide (I), Irbesartan 
(II)  and  Olmesartan Medoxomil (III) at ambient temperature, using Atlantis 4.6  mm x 
250 mm RP-C18 Column, with a  flow rate of  1.5  ml.min-1, and  UV. Detector at 288 
nm and 260 nm for (I) and (II and III), respectively. By adopting the entioned 
chromatographic technique, (I) and (III) were determined in the presence of their acidic 
and alkaline-degradates separately   as   stability-indicating   methods utilizing phosphate 
buffer pH= 3:acetonitrile (60:40, v/v),  phosphate  buffer  pH  =  3.2:acetonitrile (60:40, v/v) 
as a mobile phase, respectively, while (II) was determined in presence of 
Hydrochlorothiazide (HCTZ), using phosphate buffer pH = 4:acetonitrile (70 :30, v/v. The 
obtained results were statistically  compared  to  the  reference  methods  of analysis  
[for  I and  "II  and  III", respectively] and no significant differences were found. 
A.T. Hemke et al., UV spectrophotometric determination of 
hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation. UV 
spectrophotometric method includes simultaneous equation method (Method I) 271.5 
nm and 257.0 nm Ȝmax of both the drugs were selected, absorbance Ratio method 
(Method   II)261.5 nm an isoabsorptive wavelength and 257.0 nm were selected for 
estimation of hydrochlorothiazide and  olmesartan  medoxomil respectively. The two 
drugs follow Beer’s law over the concentration range of 5-25 µg/mL.  The % recoveries of 
the    both the drugs were found to be nearly 100 % representing the accuracy of the 
proposed methods. Validation of the proposed methods was carried out for its accuracy, 
precision,  specificity  and  ruggedness  according   to   ICH  guidelines. The proposed 
methods can be successfully applied in routine work for the determination of 
hydrochlorothiazide and olmesartan medoximil in combined dosage form. 
Agyilirah GA, Green M, Ducret R. Evaluation of gastric retention properties of 
cross linked polymer-   coated   tablet   versus   those   of non disintegrating tablets.            
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G, Caldero SG, Chen L, et al. (May 2014). "Histopathological changes in the 
gastrointestinal tract due to medications: an update for the surgical pathologist (part II of 
II)". Int. J. Surg. Pathol. 22 (3). 
C. Narendra et al., developed an optimized gastric floating drug delivery  system  
(GFDDS)  containing metoprolol  tartrate  (MT)  as   a model drug by the optimization 
technique. A 23 factorial design was employedin formulating the GFDDS with total 
polymer  content-to  drug ratio (X1), polymer-to-polymer ratio (X2), and different viscosity 
grades of hydroxypropyl methyl cellulose (HPMC) (X3) as independent variables.  Four 
dependent variables were considered: percentage of MT release at 8 hours, T50%, 
diffusion coefficient, and floating time. The main effect and interaction terms were 
quantitatively evaluated using a  mathematical model. The results indicate that X1 and 
X2 significantly affected the floating time and release properties, but the effect of 
different viscosity grades of HPMC (K4M and K10M) was no significant. Regression 
analysis and numerical optimization were performed to identify the best formulation. 
Fickian release transport was confirmed as the release mechanism from the optimized 
formulation.  
Chen YC, Ho H, Lee TY, Sheu MT. Physical characterizations and sustained 
release profiling of gastroretentive drug delivery system with improved floating and 
swelling capabilities. International Journal Of Pharmaceutics, 2013. 
Deckanth Sharma Oral delivery of drugs is by far the most preferable route of 
drug delivery. This route has high patient acceptability, primarily due to ease of 
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administration. Effective oral drug delivery depend upon the factors such as gastric 
emptying process, gastrointestinal transit time of the dosage form ,drug release from the 
dosage form, and site of absorption of drug. In the recent years, scientific and 
technological advancement have been made in the research and development of 
gastroretentive drug delivery system. Henceforth a wide spectrum of dosage form have 
been developed for the drugs which have narrow absorption window, unstable at 
intestinal pH , soluble in acidic pH and have site of action specific to stomach.The 
purpose of writing this review was to investigate, compile and present  the recent as 
well as past literatures in more concise way with special focus on approaches which are 
currently utilized in the prolongation of gastric residence time. These includes floating 
system, swelling and expanding system, bio/mucoadhesive system, high density system 
and other delayed gastric emptying devices. The present review addresses briefly about 
the classification, formulation consideration for GRDDS, factors controlling gastric 
retention, merits , demerits and applications of gastroretentive drug delivery systems. 
Dr. S. D. Barhate et al., formulated and optimized the bilayer floating tablets  of  
famotidine,  by  using  HPMC  K100LV,  HPMC  K4MCR, sodium bicarbonate, sodium 
alginate, sodium starch glycolate, croscarmellose,  crospovidone  and  lactose.  Box-
Behnken  factorial design was used to statistically optimize the controlled release layer 
composition and  evaluation  of  the  effect  of   amount  of   HPMC   K100LV (X1), 
amount of HPMC K4MCR (X2) and amount of sodium bicarbonate (X3) on release rate of 
famotidine. The polymers HPMC K100LV,  HPMC  K4MCR  showed  better  control  
over  drug  release. The formulated formulations of Box-Behnken factorial design 
showed zero- order     drug      release.      The     prognostic      ability      of 
Response Surface Methodology involving multiple response optimizations was 
proved in  designing  and  optimization  of  controlled release pharmaceutical 
formulations. Response surface prediction   plots   are  useful   to   show   the    
effect    of   interactions on the responses and desirability approach  is  a promising 
tool for optimization. 
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Garg AK, Kapoor G, Sachdeva RK. Formulation and evaluation of nizatidine 
floating tablets. American Journal of pharmatech Research, 2012. 
Girish S. Sonar et al., prepared and performed in vitro evaluation  of bilayer and 
floating-bioadhesive tablets of  rosiglitazone  maleate  Tablets were characterized using 
the official method. Hydroxypropyl methylcellulose (HPMC) and sodium bicarbonate 
were added to  the  floating layer and, when immersed in 0.1 mol/l HCl, the tablet 
expands and rises to the surface where the drug is gradually released without 
interference from gas bubbles. The in vitro drug release from the  tablet was controlled 
by the amount of HPMC  in the  sustained  release  layer. The release of rosiglitazone 
maleate from the tablets followed the matrix first- order release model. 
Hünseler, C; Paneitz, A; Friedrich, D; Lindner, U; Oberthuer, A; Körber, F; 
Schmitt, K; Welzing, L; Müller, A; Herkenrath, P; Hoppe, B; Gortner, L; Roth, B; Kattner, 
E;  Schaible, T (Jan 2011). "Angiotensin II receptor blocker induced fetopathy: 7 cases". 
Klin Padiatr. "BENICAR Prescribing Information" (PDF). Retrieved 2011-01-20. De 
Petris G, Caldero SG, Chen L, et al. (May 2014). "Histopathological changes in the 
gastrointestinal tract due to medications: an update for the surgical pathologist (part II of 
II)". Int. J. Surg. Pathol. Chandel A, Chauhan K. Gastroretentive approaches. Aulakh 
GK, Sodhi RK, Singh M (August 2007), "An update on non-peptide angiotensin receptor 
antagonists and related RAAS modulators",  
Jamil F, Sunil K, Sharma S, Vishvakarma P, Singh L. Review on stomach 
specific drug delivery :development and evaluation. IJRPBS, 2011. 
JH Guo., used a two roll milling method to prepare a new  bioadhesive polymer 
patch formulation for controlled drug delivery consisting of CP, PIB and PIP. The 
strongest peel strength was found on buccal patches with a CP: PIB: PIP ratio of 
50:43.75:6.25. He developed a formulation for buprenorphine - controlled delivery 
consisting of polyisobutylene, polyisoprene, and carboapol 934P. It was observed that 
the milling process did not change the thermal, rheological, or viscous properties of the 
individual polymers used. 
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Khan R. Gastroretentive Drug Delivery Sytem – A Review. Int J Pharm Bio Sci, 
2013. Kotreka U and Adeyeye MC. Gastroretentive floating drug delivery system a 
review. Therapeutic Drug Carrier System, 2011. Krogel I and Bodmeier R. floating or 
pulsatile drug delivery system based on coated effervescent cores. International Journal 
of Pharmaceutics, 1999. 
Mayavanshi AV and Gajjar SS. Floating drug delivery system to increase gastric 
retention of drugs. RJPT, 2008. Patel GM, Patel HR, Patel M. Floating drug delivery 
system an innovative approaches to prolong gastric retention. Pharmainfo.net 2007. 
"Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in 
Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic 
Nephropathy". 
Pawar HA, Gharat PR, Dhavale RV, Joshi PR, Rakshit PP, Development and 
evaluation of gastroretentive floating tablets of an antihypertensive drug using 
hydrogenated cottonseed oil. ISRN, 2013. Pawar V.K, Shaswat K, Garg G, Awasthi R. 
Gastroretentive dosage form: A review with special emphasis on floating drug delivery 
systems, Informa Healthcare 2011. 
Pawar HA, Gharat PR, Dhavale RV, Joshi PR, Rakshit PP, Development and 
evaluation of gastroretentive floating tablets of an antihypertensive drug using 
hydrogenated cottonseed oil. ISRN,  2013. 
Prabhakar K. Verma et al., spectrophotometric estimation of olmesartan 
medoxomil in tablet dosage form with stability studies.  A  simple accurate and precise 
spectroscopic method was developed for determination of Olmesartan medoxomil in 
tablets. The dA/dȜ was measured at 257nm for Olmesartan and calibration curves were 
plotted as dA/dȜ versus concentration respectively. The method was found to  be linear 
from 2-20ȝg/mL for Olmesartan (r2 ≥ 0.9979) at 257nm.  The within day and between 
day variation showed coefficient of  variation (CV%) valued less than 1.6% for drug. The 
limit of detection was 0.13µg/mL for Olmesartan. Results of analysis for method were 
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validated statistically and by recovery studies. The proposed method is economical and 
sensitive for the estimation of Olmesartan in  bulk  drug  and  its tablet dosage form. 
Prajapati DV, Jani GK, Khutliwala TA, Zala BS. Raft forming system- An 
upcoming approach of gastroretentive drug delivery system. Journal of Controlled 
Release, 2013. 
R Preston Mason, Cardiovascular Division, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, MA, and Elucida Research, Beverly, MA, USA. 
Vascular Health and Risk Management, Optimal therapeutic strategy for treating 
patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. 
Retrieved January 5,2013. 
Talukder R, Fassihi R. Gastroretentive delivery systems. Drug development and 
industrial pharmacy,2004.. 
Vinod KR, Vasa S, Anbuazagahan S. Approaches for gastroretentive drug 
delivery, IJABPT, 2008. Vyas SP, Khar RK. Controlled drug delivery: concept and 
advances. Vallabh prakashan Delhi, Waterman KC. A critical review of gastric retentive 
controlled drug delivery. Pharmaceutical Development and Technology, 2007. 
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DRUG PROFILE 
 
Olmesartan medoxomil 
Olmesartan medoxomil is described 
chemically as 2,3-dihydroxy-2-butenyl 4-(1 
hydroxy-1- methylethyl)-2-propyl-1-[p-(o-1H-
tetrazol-5-ylphenyl)benzyl]imidazole-5 
carboxylate, cyclic 2,3- carbonate. 
 
 
Generic Name: olmesartan (OL-me-SAR-tan) 
Brand Name: Benicar 
Trade names Olmecip. 
Pregnancy 
category 
           C (D if used in second or third trimester) 
Routes of 
administration 
Oral 
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Legal status 
Legal status  In general: ℞ (Prescription only) 
Pharmacokinetic data 
Bioavailability 26% 
Metabolism Hepatic (cannot be removed by hemodialysis) 
Biological half-life 13 hours 
Excretion Renal 40%, biliary 60% 
Identifiers 
Chemical and physical data 
Formula  C29H30N6O6 
Molar mass 558.585 g/mol 
Olmesartan medoxomil is an angiotensin II receptor antagonist which has been 
used for the treatment of high blood pressure. It was developed by Sankyo in 1995, and 
is sold under the trade name Benicar Olmecip(Cipla)Olsar (Unichem Laboratories). An 
ester prodrug, it is completely and rapidly hydrolyzed to the active acid form, olmesartan 
(RNH-6270).(48) 
Indications 
Olmesartan is indicated for the treatment of hypertension. It may be used alone 
or in combination with other antihypertensive agents.(49) The U.S. Food and Drug 
Administration (FDA) has determined that the benefits of Benicar continue to outweigh 
its potential risks when used for the treatment of patients with high blood pressure 
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according to the drug label.(50)Treating high blood pressure alone or with other 
medicines. It may also be used for other conditions as determined by your doctor. 
Olmesartan is an angiotensin II receptor blocker (ARB). It works by relaxing 
blood vessels. This helps to lower blood pressure. 
Before using olmesartan: 
Some medical conditions may interact with olmesartan. Tell your doctor or 
pharmacist if you have any medical conditions, especially if any of the following apply to 
you: 
 if you are pregnant, planning to become pregnant, or are breast-feeding 
 if you are able to become pregnant. 
 if you are taking any prescription or nonprescription medicine, herbal 
preparation, or dietary supplement. 
 if you have allergies to medicines, foods, or other substances. 
 if you have a history of angioedema (eg, swelling of the hands, face, lips, 
eyes, throat, or tongue; difficulty swallowing or breathing; hoarseness), 
including angioedema caused by treatment with an angiotensin-converting 
enzyme (ACE) inhibitor (eg, lisinopril). 
 if you have a history of heart problems (eg, heart failure), blood vessel 
problems, blood flow problems, liver or kidney problems, diabetes, or 
gallbladder problems. 
 if you have a history of stroke or recent heart attack. 
 if you are dehydrated or have low blood volume. 
 if you have electrolyte problems (eg, high blood potassium levels, low blood 
sodium levels) or are on a low-salt (sodium) diet. 
 if you are on dialysis. 
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SOME MEDICINES MAY INTERACT with olmesartan.  
 Diuretics (eg, furosemide, hydrochlorothiazide) because the risk of low blood 
pressure may be increased. 
 Potassium-sparing diuretics (eg, spironolactone, triamterene) or potassium 
supplements because the risk of high blood potassium levels may be increased 
 ACE inhibitors (eg, lisinopril) or aliskiren because the risk of certain side effects 
(eg, kidney problems, high blood potassium levels, low blood pressure) may be 
increased. 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, celecoxib, ibuprofen, 
naproxen) because they may decrease olmesartan's effectiveness and the risk 
of serious kidney problems may be increased. 
 Lithium because the risk of its side effects may be increased by olmesartan. 
This may not be a complete list of all interactions that may occur. Ask your health 
care provider if olmesartan may interact with other medicines that you take. Check with 
your health care provider before you start, stop, or change the dose of any medicine. 
Olmesartan is used alone or in combination with other medications to treat high 
blood pressure in adults and children 6 years of age and older. Olmesartan is in a class 
of medications called angiotensin II receptor antagonists. It works by blocking the action 
of certain natural substances that tighten the blood vessels, allowing the blood to flow 
more smoothly and the heart to pump more efficiently. 
High blood pressure is a common condition and when not treated, can cause 
damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage 
to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney 
failure, loss of vision, and other problems. In addition to taking medication, making 
lifestyle changes will also help to control your blood pressure. These changes include 
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eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 
30 minutes most days, not smoking, and using alcohol in moderation. 
Contraindications 
Contraindications for treatment with olmesartan include biliary obstruction. 
Another major contraindication is pregnancy; reports in the scientific literature reveal 
fetal malformations for pregnant women taking sartan-derived drugs.(51) 
Adverse effects 
The incidence of adverse effects with Benicar (the US trade name for olmesartan 
medoxomil) is reported as similar to placebo; the only adverse effect that occurred in 
>1% of patients treated with it and more frequently than placebo was dizziness (3% vs 
1%). The full prescribing information for Benicar notes as with all drugs that act directly 
on the renin-angiotensin system, olmesartan is contraindicated in pregnancy and can 
cause injury and even death to the developing fetus. In studies of angiotensin II receptor 
antagonists such as olmesartan, patients with unilateral or bilateral renal artery 
stenosis, increases in serum creatinine or blood urea nitrogen have been reported. 
There has been no long-term use of olmesartan medoxomil in patients with unilateral or 
bilateral renal artery stenosis, but similar results may be expected.(52) Rarely, 
olmesartan can cause severe gastrointestinal issues. The symptoms, which include 
nausea, vomiting, diarrhea, weight loss, and electrolyte abnormalities, are common 
among those who have celiac disease.(53) Recent studies suggested this form of 
sprue-like enteropathy could be caused by the inhibition of TGF-ȕ, a polypeptide 
cytokine that maintains intestinal homeostasis. However, it is still unclear why this action 
was never observed with other ARBs.(54) 
Dosage and administration 
The usual recommended starting dose of olmesartan is 20 mg once daily. The 
dose may be increased to 40 mg after two weeks of therapy, if further reduction in blood 
pressure is desirable. Doses above 40 mg do not appear to have greater effect, and 
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twice-daily dosing offers no advantage over the same total dose given once daily.No 
adjustment of dosage is typically necessary for advanced age, renal impairment, or 
hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g., 
patients treated with diuretics), olmesartan should be initiated with caution; 
consideration should be given to use of a lower starting dose in such cases. If blood 
pressure is not controlled by Benicar alone, a diuretic may be added. Benicar may be 
administered with other antihypertensive agents. Benicar may be administered with or 
without food. 
Preparations 
Olmesartan and Sevikar HCT combined is marketed worldwide by Daiichi 
Sankyo, in India by Abbott Healthcare Pvt. Ltd. under the trade name WinBP, by Zydus 
Cadila under the trade name Olmy, by Ranbaxy Laboratories Ltd. under the trade name 
Olvance, Olsar by Unichem Laboratories and in Canada by Schering-Plough as 
Olmetec. Several preparations containing olmesartan and other antihypertensives are 
available. Teva Pharmaceuticals produces a formulation containing olmesartan, 
amlodipine, and hydrochlorothiazide for once daily use.(55) Benicar HCT is the brand 
name of a medication containing olmesartan medoxomil in combination with 
hydrochlorothiazide. Benitec H, another medication containing olmesartan medoxomil 
and hydrochlorothiazide, is marketed by GlaxoSmithKline in India. 
Research 
Two clinical studies (MORE  and OLIVUS(56)(57)report that Benicar reduced 
arterial plaque during therapy for high blood pressure. 
In a small study with 44 patients with chronic kidney disease without a history of 
diabetes, olmesartan was more effective in reducing daily urinary protein (proteinuria) 
than losartan, valsartan, and candesartan.(58) 
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Other uses for this medicine 
Olmesartan is also sometimes used to treat heart failure (condition in which the 
heart is unable to pump enough blood to the rest of the body) and diabetic nephropathy 
(kidney disease in people with diabetes and high blood pressure). Talk to your doctor 
about the possible risks of using this medication for your condition. 
This medication may be prescribed for other uses; ask your doctor or pharmacist 
for more information. 
Storage 
Keep this medication in the container it came in, tightly closed, and out of reach 
of children. Store it at room temperature and away from excess heat and moisture (not 
in the bathroom). 
Unneeded medications should be disposed of in special ways to ensure that 
pets, children, and other people cannot consume them. However, you should not flush 
this medication down the toilet. Instead, the best way to dispose of your medication is 
through a medicine take-back program. Talk to your pharmacist or contact your local 
garbage/recycling department to learn about take-back programs in your community. 
Symptoms of overdose may include:  
 fainting 
 dizziness 
 fast or slow heartbeat 
WARNING 
FETAL TOXICITY 
 When pregnancy is detected, discontinue Benicar as soon as possible [see 
WARNINGS AND PRECAUTIONS] 
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 Drugs that act directly on the renin-angiotens in system can cause injury and 
death to the developing fetus [see WARNINGS AND PRECAUTIONS]. 
Olmesartan is used alone or in combination with other medications to treat high 
blood pressure in adults and children 6 years of age and older. Olmesartan is in a class 
of medications called angiotensin II receptor antagonists. It works by blocking the action 
of certain natural substances that tighten the blood vessels, allowing the blood to flow 
more smoothly and the heart to pump more efficiently. 
High blood pressure is a common condition and when not treated, can cause 
damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage 
to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney 
failure, loss of vision, and other problems. In addition to taking medication, making 
lifestyle changes will also help to control your blood pressure. These changes include 
eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 
30 minutes most days, not smoking, and using alcohol in moderation. 
Olmesartan may cause side effects. 
 swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs 
 severe diarrhea 
 weight loss 
 difficulty breathing or swallowing 
 hoarseness 
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Hypromellose 
Hypromellose 
 
Names 
Other names  
Hydroxypropyl methylcellulose; hydroxypropyl methyl cellulose; HPMC; E464 
Identifiers 
CAS Number  9004-65-3  
ChemSpider  21241863  
ECHA InfoCard 100.115.379 
E number E464 (thickeners, ...) 
 
 36SFW2JZ0W  
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Properties 
Chemical formula Variable 
Molar mass Variable 
Pharmacology 
ATC code S01KA02 (WHO) 
Hypromellose (INN), short for hydroxypropyl methylcellulose (HPMC), is a 
semisynthetic, inert, viscoelastic polymer used as eye drops, as well as an excipient 
and controlled-delivery component in oral medicaments, found in a variety of 
commercial products.(59) 
As a food additive, hypromellose is an emulsifier, thickening and suspending 
agent, and an alternative to animal gelatin. Its Codex Alimentarius code (E number) is 
E464. 
Chemistry 
Hypromellose is a solid, and is a slightly off-white to beige powder in appearance 
and may be formed into granules. The compound forms colloids when dissolved in 
water. This non-toxic ingredient is combustible and can react vigorously with oxidising 
agents.[4] 
Hypromellose in an aqueous solution, unlike methylcellulose, exhibits a thermal 
gelation property. That is, when the solution heats up to a critical temperature, the 
solution congeals into a non-flowable but semi-flexible mass. Typically, this critical 
(congealing) temperature is inversely related to both the solution concentration of 
HPMC and the concentration of the methoxy group within the HPMC molecule (which in 
turn depends on both the degree of substitution of the methoxy group and the molar 
substitution. That is, the higher the concentration of the methoxy group, the lower the 
critical temperature. The inflexibility/viscosity of the resulting mass, however, is directly 
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related to the concentration of the methoxy group (the higher the concentration, the 
more viscous or less flexible the resulting mass is). 
Uses 
There are many fields of application for hypromellose, including: 
 Tile adhesives 
 Cement renders 
 Gypsum products 
 Pharmaceutical 
 Paints & coatings 
 Food 
 Cosmetics 
 Detergents & cleaners 
 Eye drops 
 Contact lenses 
Excipient/tableting ingredient 
In addition to its use in ophthalmic liquids, hypromellose has been used as an 
excipient in oral tablet and capsule formulations, where, depending on the grade, it 
functions as controlled release agent to delay the release of a medicinal compound into 
the digestive tract. It is also used as a binder and as a component of tablet coatings.(60) 
Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption 
from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II 
receptor antagonist. Angiotensin II is formed from angiotensin I in a reaction catalyzed  
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by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal 
pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, 
stimulation of  synthesis  and  release of aldosterone, cardiac stimulation and  renal 
reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II 
by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular 
smooth muscle. Its action is, therefore, independent of the pathways for  angiotensin II 
synthesis. Olmesartan medoxomilis indicated for the treatment of mild to moderate 
essential hypertension. The absolute bioavailability of olmesartan is approximately 26%. 
After oral administration, the peak plasma concentration (Cmax) of olmesartan is 
reached after 1 to 2 hours. Food does not affect the  bioavailability of 
olmesartan.Olmesartan medoxomil inhibits the pressor effect of an angiotensin II 
infusion   in a dose- dependent manner at doses of 2.5 to 40 mg. The inhibition was 
90% at doses of olmesartan medoxomil >40 mg 24 hours post  dose. 
 
Drug excipients compatibility study Fourier Transform Infrared  
(FTIR) 
Drug excipients interactions play vital role in  the  release of drug from the  
formulation.  Fourier  Transform Infrared spectroscopy has  been  used  to study the 
physical and chemical  interaction  between  the excipients used. FTIR technique has 
been used to study the physical and chemical interaction between drug and excipients 
used.   
Powder flow property 
The flow properties of powder were determined  included  the  following:  bulk  
density,  tapped  density , carr’s index, Hausner’s ratio and angle of repose. All   the 
above properties were measured according to USP XXXI. 
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SODIUM BICORBONATE 
 
Names 
IUPAC name 
Sodium hydrogen carbonate 
Other names 
Baking soda, bicarb (laboratory slang), bicarbonate of 
soda, nahcolite 
Properties 
Chemical formula NaHCO3 
Molar mass 84.0066 g mol−1 
Appearance White crystals 
Odor Odorless 
Density  2.20 g/cm3 as solid 
 1.1 to 1.3 as powder 
Melting point (Decomposes to sodium carbonate starting at 50 °C 
DEPARTMENT OF PHARMACEUTICS Page 49 
 
Solubility in water   69 g/L (0 °C)  
 96 g/L (20 °C)  
 165 g/L (60 °C)  
 236 g/L (100 °C)  
Solubility 0.02 wt% acetone, 2.13 wt% methanol 
@22 °C.[5]insoluble in ethanol 
log P −0.82 
Acidity (pKa)  10.329 
 6.351 (carbonic acid)  
Refractive index (nD) nα = 1.377 nȕ = 1.501 nȖ = 1.583 
Structure 
Crystal structure Monoclinic 
Thermochemistry 
Specific 
heat capacity (C) 
87.61 J/mol K 
Std molar 
entropy (So298) 
102 J/mol K 
Std enthalpy of 
formation (ΔfHo298) 
−947.7 kJ/mol 
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Gibbs free energy (ΔfG˚) −851.9 kJ/mol 
Pharmacology 
ATC code B05CB04 (WHO) B05XA02 (WHO), QG04BQ01 
(WHO) 
Routes of 
administration 
Intravenous, oral 
                                    
Sodium bicarbonate (IUPAC name: sodium hydrogen carbonate) is 
a chemical compound with the formula NaHCO3. It is a salt composed of sodium ions 
and bicarbonate ions. Sodium bicarbonate is a white solid that is crystalline but often 
appears as a fine powder. It has a slightly salty, alkaline taste resembling that of 
washing soda (sodium carbonate). The natural mineral form is nahcolite. It is a 
component of the mineral natron and is found dissolved in many mineral springs. It is 
among the food additives encoded by the European Union, identified as E 500. 
Since it has long been known and is widely used, the salt has many related 
names such as baking soda, bread soda, cooking soda, and bicarbonate of soda. 
In colloquial usage, the names sodium bicarbonate and bicarbonate of soda are often 
truncated. Forms such as sodium bicarb, bicarb soda, bicarbonate, bicarb, or even bica 
are common. The word saleratus, from Latin sal æratus meaning "aerated salt", was 
widely used in the 19th century for both sodium bicarbonate and potassium bicarbonate. 
Alkalinity/pH increase 
It can be administered to pools, spas, and garden ponds to raise the total 
alkalinity, this will also raise the pH level and make maintaining proper pH easier. In the 
event that the pH is low and the alkalinity is adequate or high, Baking Soda (sodium 
bicarbonate) should not be used to adjust the pH.  
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Neutralisation of acids and bases 
Sodium bicarbonate is amphoteric, reacting with acids and bases. It reacts 
violently with acids, releasing CO2 gas as a reaction product. It is commonly used to 
neutralize unwanted acid solutions or acid spills in chemical laboratories. 
A wide variety of applications follows from its neutralisation properties, including 
reducing the spread of white phosphorus from incendiary bullets inside an afflicted 
soldier's wounds. 
Medical uses 
Sodium bicarbonate mixed with water can be used as an antacid to treat acid 
indigestion and heartburn. Its reaction with stomach acid produces salt, water, 
and carbon dioxide: 
NaHCO3 + HCl → NaCl + H2O + CO2(g) 
Intravenous sodium bicarbonate is an aqueous solution that is sometimes used 
for cases of acidosis, or when insufficient sodium or bicarbonate ions are in the 
blood.[25] In cases of respiratory acidosis, the infused bicarbonate ion drives the 
carbonic acid/bicarbonate buffer of plasma to the left and, thus, raises the pH. It is for 
this reason that sodium bicarbonate is used in medically supervised cardiopulmonary 
resuscitation. Infusion of bicarbonate is indicated only when the blood pH is markedly 
(<7.1–7.0) low.  
It is used for treatment of hyperkalemia, as it will drive K+ back into cells during 
periods of acidosis.]Since sodium bicarbonate can cause alkalosis, it is sometimes used 
to treat aspirin overdoses. Aspirin requires an acidic environment for proper absorption, 
and the basic environment diminishes aspirin absorption in the case of an 
overdose. Sodium bicarbonate has also been used in the treatment of tricyclic 
antidepressant overdose. It can also be applied topically as a paste, with three parts 
baking soda to one part water, to relieve some kinds of insect bites and stings (as well 
as accompanying swelling).  
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Sodium bicarbonate has been found to have no effect on the blood pressure of 
several types of rat models susceptible to salt-sensitive hypertension, in contrast 
with sodium chloride. This was ascribed to the high concentration of chloride, rather 
than the sodium content in dietary salts.  
Sodium bicarbonate can be used to treat an allergic reaction to plants such 
as poison ivy, poison oak, or poison sumac to relieve some of the associated itching.  
Bicarbonate of soda can also be useful in removing splinters from the skin.  
Some alternative practitioners, such as Tullio Simoncini, have promoted baking 
soda as a cancer cure, which the American Cancer Society has warned against due to 
both its unproven effectiveness and potential danger in use.  
Sodium bicarbonate can be added to local anaesthetics, to speed up the onset of 
their effects and make their injection less painful. It is also a component of Moffett's 
solution, used in nasal surgery. 
Magnesium stearate 
Uses 
Magnesium stearate is often used as an anti-adherent in the manufacture of 
medical tablets, capsules and powders.[4] In this regard, the substance is also useful, 
because it has lubricating properties, preventing ingredients from sticking to 
manufacturing equipment during the compression of chemical powders into solid 
tablets; magnesium stearate is the most commonly used lubricant for tablets. 
Magnesium stearate can also be used efficiently in dry coating processes.  
Magnesium stearate is also used to bind sugar in hard candies like mints, and is 
a common ingredient in baby formulas. 
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Safety 
Magnesium Stearate is generally considered safe for human consumption at 
levels below 2500 mg/kg per day. In 1979, the FDA's Subcommittee on GRAS 
(generally recognized as safe) Substances (SCOGS) reported, "There is no evidence in 
the available information on ... magnesium stearate ... that demonstrates, or suggests 
reasonable grounds to suspect, a hazard to the public when they are used at levels that 
are now current and in the manner now practiced, or which might reasonably be 
expected in the future. 
TALC 
Talc is a clay mineral composed of hydrated magnesium silicate with the 
chemical formula H2Mg3(SiO3)4 or Mg3Si4O10(OH)2. In loose form, it, along with corn 
starch, was one of the most widely used substances known as baby powder (in the 
case of talc, often called simply  talcum powder; It occurs 
as foliated to fibrous masses, and in an exceptionally rare crystal form. It has a 
perfect basal cleavage, and the folia are not elastic, although slightly flexible. use as 
a cosmetic (talcum powder), as a lubricant, and as a filler in paper manufacture 
Industrial grade 
In the United States, the Occupational Safety and Health 
Administration and National Institute for Occupational Safety and Health have set 
occupational exposure limits to respirable talc dusts at 2 mg/m3 over an eight-hour 
workday. At levels of 1000 mg/m3, inhalation of talc is considered immediately 
dangerous to life and health 
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MATERIALS AND METHODS 
Olmesartan medoxomil was obtained as a gift sample from Micro labs Pharma Ltd. 
Hosur. HPMC K4M, HPMC K100M were obtained from Atoz pharma, pondicherry. All 
other reagents used were of analytical grade. 
Preparation of standard curve of olmesartan medxomil in 
methanol 
Accurately weighed olmesartan medoxomil (10  mg)  was placed in 100 ml 
volumetric flask, 10 ml of methanol was added to it and sonicate for 1 minute and then 
made up the volume to 100 ml with  methanol. From the above solution, 1 ml of solution  
was  pipette out and diluted to 10 ml with methanol. The resultant solution obtained was 
10 µg/ml and was scanned in UV range of 200 to 400  nm.  Olmesartan  medoxomil 
showed maximum absorbance at 257  nm.  Thus,  257 nm was taken as Ȝmax. 
Preparation of floating tablets of olmesartan medoxomil 
The composition of different formulations of  Olmesartan Medoxomil floating 
tablets is  shown  in table 1. Direct compression method had been employed to prepare 
floating tablets of Olmesartan Medoxomil with HPMC K4M and HPMC K100M . All 
ingredients were weighed accurately and passed through mesh #60. In order to mix 
thoroughly polymer and drug blended geometrically in mortar pestle for 15 mins and 
then sodium bicarbonate, citric acid, magnesium sterate, talc and lactose were mixed 
one by one. After thorough mixing these ingredients the powder blend was passed 
through mess #44. The tablets were compressed on rotary tablet press.[61]. 
Experimental Design 
A 32  full factorial design was used for the  optimization. 
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Optimization of floating tablets of Olmesartan Medoxomil by 32  full 
factorial design 
In the present study three levels two factors,  full factorial design was employed 
for the optimization of floating tablets of olmesartan medoxomil. The concentration of 
HPMC K4M and HPMC K100M were selected as independent variable and floating lag 
time, total floating time and T80 were selected as dependent variables. 
X1 code for amount of HPMC K4M and X2 code for amount of   HPMCK100M. 
Table no 1: Full factorial design layout 
                 
BATCH CODE X1 X2 
F1 -1 -1 
F2 -1 0 
F3 -1 1 
F4 0 -1 
F5 0 0 
F6 0 1 
F7 1 -1 
F8 1 0 
F9 1 1 
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Table no 2: Coded  values X1 code for amount  of  HPMC  K4M  and  X2 
Code for amount of HPMCK100M 
Coded 
value 
Amount of HPMC  
K4M in mg  (X1) 
Amount of HPMCK 
100 M in mg (X2) 
-1 0 0 
0 40 40 
1 80 80 
 
Formulation of factorial batches and Statistical modeling  for 
optimization 
A three level, two factor experimental design as shown below  described  the  
proportion  in  which independent variables-  concentration  of  HPMC  K4M  and   
HPMC K100M was used in the formulation. The concentration of polymer was varied at 
three level 0, 40 mg and 80  mg. floating lag time, total floating time and T80 of 9 
formulations were analysed. The run or formulation which are designed based on 
factorial design are evaluated for the response. The response values are subjected to 
multiple regression analysis to find out the relationship between the factor used and the 
response value obtained. The response values subjected for this analysis is floating lag 
time, total  floating  time  and  T80.    The  multiple  regression analysis was done using 
DESIGN EXPERT 9.0.3.1 D- optimal type. Which is specially meant for this 
optimization. Analysis of data was carried out using ANOVA and the individual 
parameter was evaluated with F test , using the regression coefficient of factor , the 
polynomial equation for each response is  generated. 
Y = b0  + b1X1  + b2X2  + b12X1X2  + b11X1
2  + b22X2
2 
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Table no 3: statistical model for  optimization 
Factor  Level  
Independent 
variables 
High(1) Medium(0) Low (-1) Dependent variable 
HPMC K4M 80 40 0 Floating lag time 
HPMC 
K100M 
80 40 0 Total floating time & 
    T 80 
 
Table no 4: Composition Of Floating Tablet Of Olmesartan Medoxomil         
Ingredients Formulations code (All the quantities are In mg.) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Olmesartan 
medoxomil 
50 50 50 50 50 50 50 50 50 
HPMC K4M 0 0 0 40 40 40 80 80 80 
HPMC K100M 0 40 80 0 40 80 0 40 80 
Sodium 
bicarbonate 
70 70 70 70 70 70 70 70 70 
Magnesium 
stearate 
8 8 8 8 8 8 8 8 8 
Talc 7 7 7 7 7 7 7 7 7 
Lactose 230 190 150 190 150 110 150 110 70 
Citric acid 35 35 35 35 35 35 35 35 35 
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Where Y is the dependent variable, b0  is  the arithmetic mean response and bi 
is the estimated coefficient  for  the  factor  Xi.  The   main   effects  (X1 and X2) 
represent  the  average  result  of  changing one factor at a time from its low to high 
value. The interaction terms (X1X2) show how the response changes when  two  factors 
are simultaneously changed. The polynomial terms(X1
2 and X 2) are included to 
investigate non linearity. On the basis of preliminary  trials  a  32  full factorial design was 
employed to study the effect  of independent variables ie concentration of HPMC K4M  
and  HPMC  K100M  on  dependent  variable  ie floating lag time, total floating time and 
T80.Analysis  of variance, contour and RSM plots represent the  effect of the 
independent variables  graphically. 
Regression Analysis Equation for  LT 
 
 
 
 
 
 
 
A: Polymer 1 (mg) 
Fig 11: Contour plot to study the effect of two HPMC grade polymer 
concentrations on     floating lag time 
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X1  =  A:  Polymer 1 X2  =  B:  Polymer 2 
 
 
 
 
 
 
                                      B: Polymer 2 (mg)          A: Polymer 1 (mg) 
Fig 12: RSM plot to study the effect of two HPMC grade polymer concentrations 
on floating lag time LT=  174.4166-1.4729X1-1.55208X2+0.0195X1X2 
 
Regression Analysis for total floating  time 
TFT (hrs) 
TFT HRS                    
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Fig 13: Contour plot to study the effect of two HPMC grade polymer 
concentrations on total floating time. 
 
 
 A: Polymer 1 (m 
 
 
 
 
                          B: Polymer 2 (mg) 
 
Fig 14: RSM plot to study the effect of two HPMC grade polymer 
concentrations on total floating time 
TFT=0.7778+0.32083X1+0.27500X2-1.87500X1X2-1.97917X12 1.6667X22 
Total floating time gives correlation co-efficient 0.7778. The P value for variable 
X1 and X2 were 0.0127  and  0.0059  respectively  (P<0.05),   it indicate that X1 and X2 
variable shown significant effect on drug release Combination co-efficient was positive 
and the P value less than 0.05, which indicates that combination of independent 
variable showed significant effect on floating lag time. The co-efficient of X1 and  X2  
were  positive  indicate  that when concentration of both the variable increase than total 
floating  time was  increased. 
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Regression Analysis for  T80 
                                                    T80 (hrs) 
 
 
 
 
 
A: Polymer 1 (mg) 
Fig 15: Contour plot to study the effect of two HPMC grade polymer 
concentrations on T80 
 
 
 
    
T80 (hrs) 
 
 
Fig 16: RSM plot to study the effect of two HPMC grade polymer    concentrations 
on T80. 
T80= 4.3333+0.07500X1+0.10000X2 
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graph representing LT, TFT and T80 
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T80 gives  correlation  co-efficient  4.3333.  The  P value for variable X1 and  X2  
were  0.0030  and 0.0007  respectively  (P<0.05),  it  indicate  that  X1 and  X2  variable    
shown  significant  effect  on   drug release. Combination co-efficient was  positive  and  
the P value less than 0.05, which indicates that combination of independent variable 
showed significant  effect  on T80. 
 
 
  
 
 
 
 
 
 
 
 
Fig 17: Comparision of TFT, LT and T80 of different formulation batches with 
respect to polymer concentration. 
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Evaluation of floating tablet:  
The prepared tablets were evaluated for the following   parameters: 
Thickness of Tablets 
The thickness of six tablets was measured using Vernier calipers. The  extent  to  
which  the  thickness of each tablet deviated from ± 5% of the  standard value was 
determined. (62) 
Hardness 
The hardness of the tablet was determined by Monsanto hardness tester. Six  
tablets  from  each batch were selected and evaluated, and the average value with 
standard deviation was  recorded.(63) 
Friability 
The Friability of tablets was performed in a Roche Friabilator. It consists of a 
plastic chamber that revolves at 25 rpm. 
Ten  tablets  were  weighed  together  and  then  placed in the chamber. The 
friabilator was operated for 100 revolutions and the tablets were subjected to the 
combined effects of abrasion and shock because the plastic chamber carrying the 
tablets drops them at a distance of six inches with every revolution. The  tablets are  
then  dusted  and  re-weighed.  The friability  (F)  is  given  by  the  formula.(64) 
 
F= W initial –W final * 100  
         W initial 
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Weight Variation 
Twenty  tablets  were  individually  weighed  and  average weight was calculated. 
The individual weight was compared to the average weight. The tablets pass  the  test  
if  not  more  than  two  tablets  are  outside  the percentage limit  and  if  no  tablet  
differs  by   more than   two  times  the  percentage  the percentage   limit. In-vitro 
buoyancy studies. 
The in vitro buoyancy was  determined  by  floating  lag time method. The 
tablets were placed in 100 ml beaker containing 0.1 N HCl. The time  required  for the 
tablets to float was determined as floating  lag  time. Total floating time was also 
determined.(65) 
In-vitro  Dissolution Studies 
In vitro dissolution study was performed by  using  USP Type II Apparatus 
(Paddle type) at 100 rpm. Dissolution test was performed using 0.1N HCL as 
dissolution medium and the temperature was maintained at 37 ± 0.5ºC. Aliquot of 
dissolution medium was withdrawn at specific time intervals 
2,4,6,8,10,12,14,16,18,20,22,24. 
The samples were filtered through a  0.45  membrane filter and diluted to  a  
suitable concentration with 0.1N HCl. Absorbance of these solutions was measured at 
257 nm UV spectrophotometer. Cumulative percentage of drug release was calculated 
using the equation  obtained from  a standard curve.(66) 
Swelling index 
The swelling index of tablets  was  determined  in  0.1N HCl (pH  1.2)  at  room  
temperature.  The swollen weight of the tablets was determined at predefined time 
intervals. The swelling index was calculated by the following  equation: 
Swelling index = (Wt  – W0/W0)*100 
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Where, W0 is the initial weight  of  tablet,  and  Wt is  the  weight  of  the  tablet 
at time t.(67) 
Kinetic modeling and mechanism of drug  release 
To know the mechanism of drug release from these formulations, The data were 
treated according to first-order (log cumulative  percentage  of  drug remaining vs 
time),  Higuchi’s  (cumulative  percentage of drug released vs square root  of  time),  
Korsmeyer (log cumulative percentage of drug released vs  log  time), equations along 
with zero order (cumulative amount of drug released vs time) pattern.  (68-70) 
Accelerated stability study 
The tablets of best batch were packed in aluminum pouch and  charged  for  
accelerated stability studies at 40 °C and 75% RH for 1 month  in  a  humidity  jar.(69) 
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RESULT AND DISCUSSION  
Standard  curve  of   Olmesartan   Medoxomil  
Standard curve of olmesartan  was  prepared  in methanol.  Standard  curve  
data  are  subjected  to linear 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18: Standard  curve  of   Olmesartan   Medoxomil 
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Identification of pure drug 
 
                                      Fig19: FTIR of   Olmesartan Medoxomil 
Drug Polymer interaction  Studies 
 
                                  Fig 20: FTIR of the  formulation 
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Olmesartan showed characterstic peak at 2974cm-1 (aliphatic C-H 
Streching),3039 cm-1 (aromatic C-H Streching), 3271cm-1 (broad peak intermolecular 
Hydrogen   bond),   3720   cm-1     (C=O   of     carboxylic group), 1483 cm-1 (C-N 
Streching). The formulation containing polymer showed all the peaks of Olmesartan 
Medoxomil  with no change in  intensity. 
Table no 5: Evaluation parameter of tablets of different   batches 
Tablet 
batch 
weight 
variation 
test(mg) 
thickness 
mm 
hardness 
(kg/cm2) 
friability % 
 
F1 398.47±2.31 4.25±0.31 5.0±0.40 0.45±0.020 
F2 398.77±2.13 3.94±.02 4.5±0.20 0.36±0.015 
F3 399.21±4.2 3.96±0.04 4.5±0.30 0.38±0.020 
F4 398.37±1.01 4.03±0.05 5.0±0.40 0.28±0.030 
F5 399.43±2.31 3.81±0.06 5.0±0.35 0.27±0.060 
F6 400.20±0.41 4.34±0.23 5.5±0.50 0.32±0.035 
F7 400.12±1.32 4.08±0.07 5.0±0.20 0.22±0.040 
F8 401.53±0.86 3.93±0.06 4.0±0.30 0.28±0.015 
F9 401.74±1.39 4.12±0.07 5.0±0.20 0.23±0.020 
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Table no 6: In vitro buoyancy  studies 
Batch Floating lag time(sec) Floating time 
F1 200 0 hrs 
F2 74 10hrs 
F3 8 12hrs. 
F4 100 11hrs. 
F5 90 16hrs. 
F6 54 15hrs. 
F7 62 14hrs. 
F8 59 15hrs 
F9 55 14hrs 
 
The in-vitro buoyancy was determined by floating lag time method. The tablets 
were placed in 100 ml  beaker containing  0.1  N  HCl.  The  time  required  for  the  
tablets  to  float  was  determined  as  floating  lag  time. 
In vitro buoyancy study showed that all the batches from F1 to F9 have 
floating lag time less than 4 minutes because of evolution and entrapment of 
carbondioxide inside the hydrated polymer matrices, resulting from the interaction 
between gas generating agent and dissolution medium which led to lowering the 
density of matrices enabling the tablets to float. 
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At  0 sec after 40 secs 
 
On the other hand, as a solvent front penetrated the polymer layer, swelling 
of HPMC K4M and HPMC K100M caused  to  increase  in  volume  of  tablet  
resulted  in     net reduction  in  density  of  the  tablet,  which   prolonged  the
 duration of floatation up to 18 hrs. 
Fig 21: Buoyancy studies of tablet at different time 
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Table no 7: Dissolution studies of different  batches 
CUMMULATIVE  PERCENT RELEASE 
 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
         
0 0 0 0 0 0 0 0 0 0 
2 38.39 18.34 17.32 22.43 19.21 17.32 19.43 20.11 11.92 
3 79.54 42.12 30.21 41.56 38.42 34.42 40.24 36.75 16.93 
5 98.22 65.86 39.42 66.76 46.34 47.59 48.25 41.44 21.84 
7  74.41 48.64 80 59.52 53.54 56.11 53.33 32.06 
8  80.64 56.42 88.53 63.54 58.67 64.66 60.51 39.46 
10  92.45 61.36 94.36 68.98 64.77 73.22 68.67 48.47 
12  98.55 67.48 97.87 72.32 70.52 78.98 75.34 55.12 
13   72.49  79.87 75.33 85.33 81.43 59.49 
14   78.87  87.41 80.32 89.89 89.54 62.11 
15   85.64  91 85.66 94.31 93.77 68.42 
16   92.48  96.73 91.29 97.75 98.24 71.45 
17   98.56   98.43   78.74 
18         81.72 
19         88.89 
20         93.21 
21         97.54 
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Invitro buoyancy study showed that all the  batches  from F1 to F9 have floating 
lag time less  than  4 minutes because of evolution and entrapment of  carbondi oxide 
inside the hydrated polymer matrices, resulting from the interaction between gas 
generating agent and dissolution medium which  led  to  lowering the density of 
matrices enabling the tablets to   float. On the other hand, as a solvent front 
penetrated the polymer layer, swelling of HPMC K4M and HPMC.K100M caused to 
increase in volume of tablet resulted in net reduction in density of the tablet, which 
prolonged the duration of floatation up to  18  hrs. Among these formulations F9 give 
the desired release and retarded the 80%  drug release for 18  hrs. 
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Fig 22: In vitro dissolution   studies of different formulation  batches 
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Fig 23: Dissolution profile of formulations F1 to  F9 
 
Table no 8:  Invitro drug release kinetics  study 
 
Model            Zero order         First order            Higuchi plot    Korsmeyer   peppas 
 
R2 0.997 0.728 0.922         0.992 
Slope 4.527 11.51 23.47 0.908 
Intercept 1.284 -6.627 -21.02 0.769 
 
The data were treated according to first-order (log cumulative percentage of drug 
remaining vs time), Higuchi’s  (cumulative  percentage  of   drug   released  vs square 
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root of time), Korsmeyer (log cumulative percentage of drug released vs log time),  
equations along with zero order (cumulative amount of drug released vs time) .The 
dissolution profile of the best batch was fitted to zero-order, first-order, Higuchi and 
korsmeyer models to ascertain the kinetic modeling of drug release. It may be 
concluded that the drug release from gastro retentive olmesartan medoxomil tablet is 
explained by zero model because R2 value of  zero  order model has 0.997. The values 
n in korsmeyer peppas equation is 0.769 which is greater  than  0.50, thus we can 
conclude that dissolution follows non  fickain diffusion. 
Swelling index 
Swelling index of the tablet include the absorption of liquid medium then 
increases the weight of the tablet. This is very important characteristics of the polymer 
which control the drug release from the formulation via diffusion from the studies it was 
found that increase the concentration of HPMC K4M increases the swelling property.F9 
showed maximum swelling among all HPMC containing formulations. HPMC K4M and 
HPMC K100M tablet when in contact with dissolution medium swell due to breakage of 
hydrogen bond between the polymer chain and form a thick gel layer and eroded 
simultaneously. This result  indicated  that the swelling index of all the formulations 
changed after different time interval.(74) 
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                            Fig 24: Swelling studies of formulation  batches 
 
Gastro retentive tablets of olmesartan medoxomil formulated in the present study 
were subjected to accelerated stability studies in Aluminum  / Aluminum pouch pack as 
aluminum  strip  is considered the best protecting packaging material but in the present 
study simulation was made using aluminum  foil pouch. As   the   dosage   form    is 
formulated for site-specific drug delivery to stomach, no change should occur in its 
floating lag time and drug dissolution profile. Dose dumping and failure   of buoyancy 
are probable effects anticipated during the stability study of such dosage forms. The 
tablets  of best batch F9 were packed in aluminum pouch and charged for accelerated 
stability studies at 40 °C and 75% RH for 1 months in a humidity jar (74).  
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Fig 25: Accelerated stability studies of the optimized  batch 
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CONCLUSION 
In the present work floating tablets of Olmesartan Medoxomil were prepared by 
direct compression.  All the tablets were  subjected  to  weight  variation, hardness, 
friability, dissolution, swelling index, drug excipient interaction studies. The tablets were 
found to be good in their integrity without any chipping, capping and sticking. 
Formulation F9 showed good result than rest of the formulations according to targets 
obtained. IR-spectroscopic studies indicated that there are no drug–excipients 
interactions. Formulation F9 showed best result with required  floating lag time of 55 
secs, total  floating time of  14  hrs and T80 of18 hrs. drug release was decreased with 
increased concentration of polymers. IR spectroscopic studies indicated that there was 
no drug excipient interactions. Kinetic studies for optimized  formulation F9 follows zero 
order and Higuchi model release systems. Zero order release describes the system 
where the drug release rate is independent of its  concentration of dissolved substance. 
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